📈 Price History

Ratio Health

— Excellent

— Good

— Average

— Poor

By Category

📊 Sector Averages

About

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

Key Ratios Snapshot

📈 Growth Pattern

⚡ Latest Quarter —

See full financials →

📊 Quick Scorecard

Loading…

🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 4 quarters analysed

Q2 2025

Confident Specific

Evidence: management repeatedly cites specific milestones (VANQUISH initiation, VENTURE-Oral enrollment completed, IND filing for amylin in Q4, manufacturing agreement). They give concrete numbers (R&D expenses, cash $808M). In Q&A they give specifics on trial design (titration schedules, doses). No defensiveness or evasion.

Q3 2025

Confident Specific

Management uses direct, quantified language (e.g., 'enrollment has been proceeding well', 'exciting to announce positive top-line results', 'we believe the data suggest no meaningful difference overall') and repeatedly cites specific milestones and timelines, projecting control over execution.

Q4 2025

Confident Specific

Management uses specific language like 'statistically significant', 'encouraging safety and tolerability', and 'well positioned' while providing clear timelines for Phase III initiation and milestones. They emphasize execution success (early enrollment completion, positive bioequivalence study) without hedging.

Q1 2026 latest

Confident Specific

Management used precise numbers (e.g., 4,500 and 1,000 patients enrolled, 14.7% weight loss in phase II, 80% achieving ≥10% weight loss) and provided clear timelines (Q3 2026 for subQ maintenance data, Q4 2026 for oral phase III start). Language like 'pleased to announce', 'substantial progress', and 'we look forward to' reinforces assuredness.

Guidance Reliability Pending · <3Q data

Investor Lens

The investment thesis is stronger after this call. The company has moved both subcutaneous and oral VK2735 into phase III registration, with rapid enrollment and clear timelines. The maintenance study expansion shows thoughtful planning for long-term differentiation. Cash of ~$600 million provides runway through key catalysts (maintenance data in Q3 2026, oral phase III initiation, amylin phase I). The only near-term uncertainty is the magnitude of weight loss in the phase III trials, especially in type 2 diabetes, and the competitive landscape. Watch for maintenance data in Q3 2026 and how the oral dual agonist competes with existing oral GLP-1s.

AI-generated concall tone analysis · Updated 2026-06-08 · Not investment advice

🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →

📊 MIXED Viking Therapeutics advances VK2735 obesity program with phase III trials and oral development.

Revenue & Profitability

Research and development expenses were $115.2 million for Q1 2026, up from $41.4 million in Q1 2025. General and administrative expenses were $14.0 million (vs. $14.1 million). Net loss was $158.3 million ($1.37 per share) compared to $45.6 million ($0.41 per share) in Q1 2025. Cash equivalents and short-term investments totaled $603 million as of March 31, 2026, down from $706 million at year-end 2025. The company had no revenue.

Outlook

Management did not provide detailed industry outlook. They noted that the launch of another oral peptide for obesity has been robust and represents market expansion rather than cannibalization of injectables. The company sees high interest in oral modalities and believes there is significant opportunity for a dual agonist oral.

Growth Drivers

Key growth drivers include advancing VK2735 subcutaneous phase III trials (VANQUISH-1 and VANQUISH-2) toward potential approval and commercialization. The oral tablet formulation of VK2735 is expected to enter phase III in Q4 2026. The maintenance dosing study (phase I) explores multiple regimens and could support long-term weight management. The amylin agonist VK3019 is expected to enter phase I soon. The company appointed a Chief Commercial Officer to lead commercialization strategy.

Balance Sheet & CapEx

Not discussed in this earnings call.

Margins

Not discussed in this earnings call. The company is pre-revenue with a net loss reported.

Key Risks

Risks flagged include forward-looking statement cautions about development activities, timelines, and milestones. The company noted that type 2 diabetes patients may be more resistant to weight loss in clinical trials. Operational risks include scaling manufacturing and ensuring supply chain efficiency. The phase III trials have 78-week primary endpoints, with extension studies and long-term data needed for approval.

Generated by AI · Q1 2026 results · Not investment advice

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-07-29

Pipeline advanced with fully enrolled phase III VK2735 trials and initiation of VK3019 phase I. R&D expenses and net loss rose sharply year-over-year, but cash reserves remain strong, supporting ongoing and future studies. Oral VK2735 phase III trials are set for Q4 2026.

Q1 2026 Q1 2026 2026-04-29

Q1 2026 saw major clinical progress for VK2735 in both injectable and oral forms, with phase III trials fully enrolled and a maintenance dosing study expanded. R&D expenses drove a higher net loss, but cash reserves remain strong, supporting operations into 2028.

Q4 2025 Q4 2025 2026-02-11

Multiple clinical milestones achieved in 2025, including advancing both subcutaneous and oral VK2735 into late-stage trials, with strong efficacy and safety data. Net loss increased due to higher R&D spend, but cash reserves remain strong to fund upcoming Phase III trials and new programs.

Q3 2025 Q3 2025 2025-10-22

Positive Phase 2 results for oral VK2735 and rapid Phase 3 enrollment highlight strong clinical progress, with robust cash reserves supporting ongoing trials. R&D expenses rose sharply, driving higher net losses, but financial resources remain sufficient for planned programs.

Q2 2025 Q2 2025 2025-07-23

Advanced VK2735 obesity program with phase III trials underway and phase II oral study enrollment completed. Q2 net loss widened to $65.6M on higher R&D and G&A expenses, with $808M in cash supporting ongoing development. Top-line phase II oral data and amylin IND filing expected in H2 2025.

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯

Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.

📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.